Welcome! If you have a coupon code, click here to apply it. Apply
stock
Enlivex Therapeutics Ltd
NASDAQ | ENLV
1.04
USD
0.00 (0.00%)
AT CLOSE (AS OF May 2, 2025)
$24M
MARKET CAP
-
P/E Ratio
-0.73
EPS
$1.8
52 Week High
$0.81
52 Week Low
LIFE SCIENCES
Sector
ENLV Chart
1D
Area
-79.88%
Trade Smarter
Automate your trading workflow with powerful tools — built for serious traders.
ENLV Technicals
ENLV Earnings
Yearly Income Statement (As of Dec 31, 2024)
| Field | Value (None) |
|---|---|
| Gross Profit | -$545K |
| Total Revenue | - |
| Cost Of Revenue | $545K |
| Costof Goods And Services Sold | $545K |
| Operating Income | -$16M |
| Selling General And Administrative | - |
| Research And Development | $10M |
| Operating Expenses | $15M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $545K |
| Income Before Tax | -$15M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | - |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$15M |
| Ebitda | -$14M |
| Net Income | -$15M |
Revenue & Profitability
Earnings Performance
Actual: $undefined
Estimate: $undefined
Difference: $undefined
Period Qundefined
ENLV Financials
yearly Balance Sheet (As of Dec 31, 2024)
| Field | Value (None) |
|---|---|
| Total Assets | $28M |
| Total Current Assets | $26M |
| Cash And Cash Equivalents At Carrying Value | $3.4M |
| Cash And Short Term Investments | $3.4M |
| Inventory | - |
| Current Net Receivables | $1.3M |
| Total Non Current Assets | $1.7M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $20M |
| Other Current Assets | $1.1M |
| Other Non Current Assets | - |
| Total Liabilities | $4.1M |
| Total Current Liabilities | $3.8M |
| Current Accounts Payable | $811K |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $235K |
| Total Non Current Liabilities | $299K |
| Capital Lease Obligations | - |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $534K |
| Other Current Liabilities | $2.8M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $24M |
| Treasury Stock | - |
| Retained Earnings | -$127M |
| Common Stock | $2.7M |
| Common Stock Shares Outstanding | $21M |
yearly Cash Flow (As of Dec 31, 2024)
| Field | Value (None) |
|---|---|
| Operating Cashflow | -$13M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $545K |
| Capital Expenditures | $103K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | - |
| Cashflow From Financing | $6.5M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$15M |
yearly Income Statement (As of Dec 31, 2024)
| Field | Value (None) |
|---|---|
| Gross Profit | -$545K |
| Total Revenue | - |
| Cost Of Revenue | $545K |
| Costof Goods And Services Sold | $545K |
| Operating Income | -$16M |
| Selling General And Administrative | - |
| Research And Development | $10M |
| Operating Expenses | $15M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $545K |
| Income Before Tax | -$15M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | - |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$15M |
| Ebitda | -$14M |
| Net Income | -$15M |
ENLV News
News Sentiment
The news sentiment chart shows the sentiment of news articles related to the symbol.
Enlivex Therapeutics Ltd Top Stories
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis - 21 April 2025
Biopharma exec says Bitcoin could help industry through 'biotech winter' - 21 March 2025
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis - 4 March 2025
Enlivex Announces Positive Interim Data - Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis - 3 March 2025
Enlivex Issues Urgent Statement on Fraudulent News Dissemination - 18 February 2025
Two More Public Companies Just Added Bitcoin to Their Balance Sheets - 8 January 2025
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - 11 December 2024
Enlivex Therapeutics ( ENLV ) Upgraded to Strong Buy: Here's What You Should Know - 31 October 2024
New Strong Buy Stocks for October 23rd - 23 October 2024
All You Need to Know About Enlivex Therapeutics ( ENLV ) Rating Upgrade to Buy - 11 September 2024
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis - 17 June 2024
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering - 29 May 2024
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering - 28 May 2024
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis - 16 April 2024
Enlivex ( ENLV ) Stock Plummets 51% in a Week: Here's Why - 15 April 2024
Tesla To $180? Here Are 10 Top Analyst Forecasts For Friday - Tesla ( NASDAQ:TSLA ) - 12 April 2024
Nasdaq Jumps 250 Points; Crude Oil Down 1% - Aptevo Therapeutics ( NASDAQ:APVO ) , Eliem Therapeutics ( NASDAQ:ELYM ) - 11 April 2024
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis - 11 April 2024
Dow Dips 100 Points; CarMax Earnings Miss Views - CarMax ( NYSE:KMX ) - 11 April 2024
Nasdaq Gains Over 50 Points; US Producer Prices Increase In March - Aptevo Therapeutics ( NASDAQ:APVO ) , ClearOne ( NASDAQ:CLRO ) - 11 April 2024
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis - 11 April 2024
This Biotech Reprogrammes Our Own Cells To Heal The Body - Enlivex Therapeutics ( NASDAQ:ENLV ) - 1 March 2024
Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis - Enlivex Therapeutics ( NASDAQ:ENLV ) - 23 February 2024
Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals - Enlivex Therapeutics ( NASDAQ:ENLV ) - 20 February 2024
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis - 17 January 2024
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer - MediWound ( NASDAQ:MDWD ) , Enlivex Therapeutics ( NASDAQ:ENLV ) - 21 November 2023
New Strong Buy Stocks for November 3rd - 3 November 2023
New Strong Buy Stocks for October 27th - 27 October 2023
New Strong Buy Stocks for October 19th - 19 October 2023
This Biotech Is Bringing Balance To The Body - How Homeostasis Is Critical To Fighting Everything From Sepsis To Cancer - Enlivex Therapeutics ( NASDAQ:ENLV ) - 16 June 2023
Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy - Enlivex Therapeutics ( NASDAQ:ENLV ) - 31 May 2023
Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy - 31 May 2023
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome ( CRS ) Resulting from CAR T-Cell Therapy - 8 May 2023
Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials - BeiGene ( NASDAQ:BGNE ) , Bristol-Myers Squibb ( NYSE:BMY ) - 13 April 2023
Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors - BeiGene ( NASDAQ:BGNE ) , Enlivex Therapeutics ( NASDAQ:ENLV ) - 11 April 2023
Why Pioneer Natural Resources Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - American Rebel Holdings ( NASDAQ:AREB ) , Addex Therapeutics ( NASDAQ:ADXN ) - 10 April 2023
BeiGene, Ltd. ( BGNE ) Surges 12.5%: Is This an Indication of Further Gains? - 10 April 2023
Why BeiGene Stock Jumped Thursday - 6 April 2023
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates - 4 April 2023
Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers - 20 March 2023
Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors - 25 January 2023
FDA Clears Enlivex Therapeutics' IND Application To Study Allocetra™ in Patients with Advanced Solid Malignancies - Enlivex Therapeutics ( NASDAQ:ENLV ) - 29 November 2022
Enlivex Doses First Patient in Phase I/II Trial to Evaluate Allocetra™ for Advanced Solid Tumor Treatment - Enlivex Therapeutics ( NASDAQ:ENLV ) - 15 November 2022
Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors - 15 November 2022
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors - Enlivex Therapeutics ( NASDAQ:ENLV ) , Bristol-Myers Squibb ( NYSE:BMY ) - 6 October 2022
Enlivex to Present at the 4th Macrophage-Directed Therapies Summit - 3 October 2022
Enlivex Therapeutics ( NASDAQ:ENLV ) - Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022 - 12 September 2022
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022 - 12 September 2022
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells - 29 August 2022
Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial - 24 August 2022
ENLV Profile
Enlivex Therapeutics Ltd Profile
Sector: LIFE SCIENCES
Industry: PHARMACEUTICAL PREPARATIONS
Enlivex Therapeutics Ltd. is a clinical stage immunotherapy company. The company is headquartered in Nes Ziona, Israel.
GNLN 8.51%
$0.0102
LGMK -17.45%
$0.0175
PLRZ 298.58%
$1.01
IBO 87.00%
$0.748
NVDA 2.59%
$114.5
FRGT 111.21%
$2.08
CNEY 16.36%
$0.165
RSLS 25.52%
$0.4255
TSLA 2.38%
$287.21
KIDZ
33.96%
$7.18
PLUG -1.01%
$0.8431
PLTR 6.95%
$124.28
AAPL -3.74%
$205.35
F 0.98%
$10.28
SNAP 7.92%
$8.45
AIFU -11.02%
$0.1389
AMZN -0.12%
$189.98
AAL 4.89%
$10.52
RGTI 16.30%
$10.63
NITO 21.14%
$0.283
DNN 2.10%
$1.46
LCID 0.00%
$2.53
BTOG 9.36%
$0.1893
MARA 5.09%
$14.05
INTC 3.20%
$20.62
HOOD 4.23%
$48.59
LYT -16.78%
$0.0982
XYZ -20.43%
$46.53
RIOT 7.98%
$8.39
HL -16.91%
$4.545
SOFI 1.52%
$12.7
HIMS 13.03%
$40.87
BTE 1.23%
$1.64
BTG -1.34%
$2.95
SMCI 2.99%
$33.71
FUBO -17.58%
$2.415
QBTS 13.54%
$7.925
VHAI -25.00%
$0.0009
JBLU 8.90%
$4.7697
BAC 2.20%
$41.055
AMCR 2.64%
$9.32
PFE 1.09%
$24.19
KDP 1.09%
$34.41
T -0.22%
$27.64
IQ 4.28%
$1.95
AGNC -0.23%
$8.79
LYG -0.13%
$3.755
BBD -0.62%
$2.405
CLIK 59.50%
$0.345
WULF -0.93%
$3.21
APLD 1.73%
$5.3
RIG 1.28%
$2.37
GRAB 2.52%
$4.89
ABEV -0.20%
$2.485
AGMH -21.78%
$0.0729
WBD 1.30%
$8.54
WW -20.26%
$0.5799
MSFT 2.32%
$435.28
AMD 2.22%
$98.8
ME -21.26%
$0.6063
CUTR -10.19%
$0.0969
RDDT -4.27%
$113.72
ERIC 1.34%
$8.34
SOUN 2.62%
$9.39
PONY 20.91%
$10.3499
VRN -0.08%
$5.905
NVNI -16.96%
$0.3363
NIO 2.16%
$4.015
RIVN 0.51%
$13.83
CCL 5.05%
$19.57
AUR 18.31%
$8.14
NCLH 6.83%
$17.37
GOOGL 1.69%
$164.03
NGD -0.78%
$3.84
ACHR 1.80%
$8.48
META 4.34%
$597.02
DGLY -0.89%
$0.0335
IONQ 12.93%
$30.92
ADIL -14.10%
$0.67
CLF 5.03%
$8.875
CLSK 1.61%
$8.81
EJH -32.63%
$0.2013
TLRY -6.26%
$0.4551
UBER 4.14%
$84.24
VALE 1.46%
$9.375
AG 0.43%
$5.905
SPHL 17.40%
$0.577
HLN 3.58%
$10.7
TSM 3.80%
$179.28
ARDX -24.50%
$4.13
HEPA -3.77%
$0.2811
RXRX 3.64%
$5.7
FNA 0.00%
$13.09
PAPL -29.80%
$0.1372
BERY -2.93%
$67.58
CSCO 2.08%
$59.33
IREN 2.51%
$6.53
WFC 2.72%
$73.765
PBR 2.38%
$11.62
HBAN 3.15%
$15.08
GNLN 8.51%
$0.0102
LGMK -17.45%
$0.0175
PLRZ 298.58%
$1.01
IBO 87.00%
$0.748
NVDA 2.59%
$114.5
FRGT 111.21%
$2.08
CNEY 16.36%
$0.165
RSLS 25.52%
$0.4255
TSLA 2.38%
$287.21
KIDZ
33.96%
$7.18
PLUG -1.01%
$0.8431
PLTR 6.95%
$124.28
AAPL -3.74%
$205.35
F 0.98%
$10.28
SNAP 7.92%
$8.45
AIFU -11.02%
$0.1389
AMZN -0.12%
$189.98
AAL 4.89%
$10.52
RGTI 16.30%
$10.63
NITO 21.14%
$0.283
DNN 2.10%
$1.46
LCID 0.00%
$2.53
BTOG 9.36%
$0.1893
MARA 5.09%
$14.05
INTC 3.20%
$20.62
HOOD 4.23%
$48.59
LYT -16.78%
$0.0982
XYZ -20.43%
$46.53
RIOT 7.98%
$8.39
HL -16.91%
$4.545
SOFI 1.52%
$12.7
HIMS 13.03%
$40.87
BTE 1.23%
$1.64
BTG -1.34%
$2.95
SMCI 2.99%
$33.71
FUBO -17.58%
$2.415
QBTS 13.54%
$7.925
VHAI -25.00%
$0.0009
JBLU 8.90%
$4.7697
BAC 2.20%
$41.055
AMCR 2.64%
$9.32
PFE 1.09%
$24.19
KDP 1.09%
$34.41
T -0.22%
$27.64
IQ 4.28%
$1.95
AGNC -0.23%
$8.79
LYG -0.13%
$3.755
BBD -0.62%
$2.405
CLIK 59.50%
$0.345
WULF -0.93%
$3.21
APLD 1.73%
$5.3
RIG 1.28%
$2.37
GRAB 2.52%
$4.89
ABEV -0.20%
$2.485
AGMH -21.78%
$0.0729
WBD 1.30%
$8.54
WW -20.26%
$0.5799
MSFT 2.32%
$435.28
AMD 2.22%
$98.8
ME -21.26%
$0.6063
CUTR -10.19%
$0.0969
RDDT -4.27%
$113.72
ERIC 1.34%
$8.34
SOUN 2.62%
$9.39
PONY 20.91%
$10.3499
VRN -0.08%
$5.905
NVNI -16.96%
$0.3363
NIO 2.16%
$4.015
RIVN 0.51%
$13.83
CCL 5.05%
$19.57
AUR 18.31%
$8.14
NCLH 6.83%
$17.37
GOOGL 1.69%
$164.03
NGD -0.78%
$3.84
ACHR 1.80%
$8.48
META 4.34%
$597.02
DGLY -0.89%
$0.0335
IONQ 12.93%
$30.92
ADIL -14.10%
$0.67
CLF 5.03%
$8.875
CLSK 1.61%
$8.81
EJH -32.63%
$0.2013
TLRY -6.26%
$0.4551
UBER 4.14%
$84.24
VALE 1.46%
$9.375
AG 0.43%
$5.905
SPHL 17.40%
$0.577
HLN 3.58%
$10.7
TSM 3.80%
$179.28
ARDX -24.50%
$4.13
HEPA -3.77%
$0.2811
RXRX 3.64%
$5.7
FNA 0.00%
$13.09
PAPL -29.80%
$0.1372
BERY -2.93%
$67.58
CSCO 2.08%
$59.33
IREN 2.51%
$6.53
WFC 2.72%
$73.765
PBR 2.38%
$11.62
HBAN 3.15%
$15.08
Discover more tools and features to empower your trading
Explore FeaturesQuotes and other market data may be delayed by 15 minutes or more. Financial data is provided by financial exchanges and other content providers and may be delayed as specified by financial exchanges or other data providers. AfterPullback does not verify any data and disclaims any obligation to do so. The information contained on this website is not intended as, and shall not be understood as, financial advice. The website does not operated by attorney, accountant or financial advisor and the information contained on this website is not a substitute for financial advice from a professional who is aware of the facts and circumstances of your individual situation. Nothing available on or through this website should be understood as a recommendation that you should not consult with a financial professional to address your particular information.
You have a coupon!
We've successfully recognized your coupon code. You can visit the pricing page to use it or feel free to look around first.